Table 1.
Current ongoing clinical trials on AML targeting MDM2 and MCL-1 pathways.
| Drug | Clinical Trial | Indication |
|---|---|---|
| MDM2 inhibitors | ||
| Idasanutlin + cytarabine versus cytarabine only | NCT02545283 | R/R AML |
| Venetoclax + Cobimetinib or Idasanutlin | NCT02670044 | R/R AML Ineligible for Cytotoxic Therapy |
| MK-8242 + cytarabine | NCT01451437 | R/R AML |
| HDM201+ cytarabine/anthracyclines | NCT03760445 | R/R or Newly Diagnosed AML |
| MCL-1 inhibitors | ||
| S64315 | NCT02979366 | AML and MDS |
| Venetoclax + S64315 | NCT03672695 | AML |
| AMG176 | NCT02675452 | R/R Multiple Myeloma and R/R AML |
| AMG397 | NCT03465540 | Multiple Myeloma, NHL, AML |
| AZD5991 | NCT03218683 | R/R Hematologic Malignancies including AML |
R/R, relapsed/refractory; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; NHL, Non-Hodgkin lymphoma.